comparemela.com
Home
Live Updates
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS) -December 04, 2023 at 07:02 am EST : comparemela.com
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS) -December 04, 2023 at 07:02 am EST
TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 -- Polaris Group , today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with...
Related Keywords
Taipei ,
T Ai Pei ,
Taiwan ,
Gina Lee ,
Washington University In St ,
Sarcoma Program ,
Polaris Group ,
Combo Strategy ,
Side Effects ,
Brian Van Tine ,
Lead Investigator ,
Director Developmental Therapeutics ,
Sarcoma Program Director ,
Washington University ,
Markets ,
comparemela.com © 2020. All Rights Reserved.